MARKET

PRQR

PRQR

Proqr Therapeuti
NASDAQ
2.000
-0.040
-1.96%
After Hours: 2.000 0 0.00% 19:52 12/08 EST
OPEN
2.050
PREV CLOSE
2.040
HIGH
2.130
LOW
1.910
VOLUME
215.62K
TURNOVER
0
52 WEEK HIGH
3.850
52 WEEK LOW
1.110
MARKET CAP
162.31M
P/E (TTM)
-4.3309
1D
5D
1M
3M
1Y
5Y
ProQR’s Strategic Divestiture and Strong Financial Outlook Justify Buy Rating
TipRanks · 1d ago
Proqr Therapeuti: Report of foreign issuer
Press release · 1d ago
Weekly Report: what happened at PRQR last week (1127-1201)?
Weekly Report · 5d ago
US Stocks Lower; Dow Falls Over 50 Points
The dow jones index fell over 50 points on monday. The nasdaq and the s&p 500 also traded lower. Shopify merchants accomplished a record-breaking $4.1 billion in sales on black friday. Redhill biopharma ltd. Shares shot up 130% after fda approval for talicia. Asian markets closed lower; european shares mostly lower.
Benzinga · 11/27 14:46
Weekly Report: what happened at PRQR last week (1120-1124)?
Weekly Report · 11/27 12:12
Weekly Report: what happened at PRQR last week (1113-1117)?
Weekly Report · 11/20 12:08
Weekly Report: what happened at PRQR last week (1106-1110)?
Weekly Report · 11/13 11:59
Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday
Piper sandler cut upstart holdings, inc. Price target from $35 to $27. Needham cut the price target for nxp semiconductors n.v. Raymond james boosted bluebird bio's price target. Evercore isi downgraded nextdoor holdings to in-line.
Benzinga · 11/08 12:30
More
About PRQR
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Webull offers ProQR Therapeutics NV stock information, including NASDAQ: PRQR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRQR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRQR stock methods without spending real money on the virtual paper trading platform.